Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31516363 | 0.90 | CYP2D6 (0.51) | CYP2D6ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL31516359 | 0.88 | ALDH1A1 (0.44) | CYP2D6ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL16053764 | 0.88 | L3MBTL1 (0.48) | CYP2D6ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL6335029 | 0.88 | ALDH1A1 (0.50) | CYP2D6ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL22864682 | 0.87 | L3MBTL1 (0.49) | CYP2D6ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL24729554 | 0.86 | ALDH1A1 (0.42) | CYP2D6ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL31516316 | 0.86 | OPRL1 (0.46) | CYP2D6ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL27372315 | 0.85 | ALDH1A1 (0.42) | CYP2D6ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL30751751 | 0.84 | L3MBTL1 (0.49) | CYP2D6ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL31516346 | 0.84 | CYP3A4 (0.49) | CYP2D6ALDH1A1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250800-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN S | 2005-11-10 | — | — | US | disclosed |
| US-20030119858-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2003-06-26 | — | — | US | disclosed |
| US-6489352-B2 | ANTIEPILEPTIC AGENTS; NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY | 2002-12-03 | — | — | US | disclosed |
| US-20020019540-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2002-02-14 | — | — | US | disclosed |
| US-6316638-B1 | FOR THERAPY OF EPILEPSY, FAINTNESS ATTACKS, HYPOKINESIA, CRANIAL DISORDERS, NEURODEGENERATIVE DISORDERS, DEPRESSION, ANXIETY, PANIC, PAIN, AND NEUROPATHOLOGICAL DISORDERS | WARNER-LAMBERT COMPANY | 2001-11-13 | — | — | US | disclosed |
| EP-1082306-A1 | CONFORMATIONALLY CONSTRAINED AMINO ACID COMPOUNDS HAVING AFFINITY FOR THE ALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL | WARNER-LAMBERT COMPANY (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999061424-A1 | CONFORMATIONALLY CONSTRAINED AMINO ACID COMPOUNDS HAVING AFFINITY FOR THE ALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL | WARNER-LAMBERT COMPANY (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250800-A1 | Conformationally constrained compounds as pharmaceutical agents | PYGB, GABRA6, GABRA2 | CYP2D6 713/4885ALDH1A1 976/4885MEN1 1848/4885 |
| US-20020019540-A1 | Conformationally constrained compounds as pharmaceutical agents | PYGB, SLC18A1, CDR2 | CYP2D6 599/4885ALDH1A1 390/4885MEN1 981/4885 |
| US-20030119858-A1 | Conformationally constrained compounds as pharmaceutical agents | PYGB, SLC18A1, CDR2 | CYP2D6 599/4885ALDH1A1 390/4885MEN1 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.